During myocardial ischemia, connexin 43 (Cx43) is dephosphorylated in vitro, and the subsequent opening of gap junctions formed by two opposing Cx43 hexamers was suggested to propagate ischemia/reperfusion injury. Reduction of infarct size (IS) by ischemic preconditioning (IP) involves activation of protein kinase C (PKC) and p38 mitogen activated protein kinase (MAPK), both of which can phosphorylate Cx43. We now studied in anesthetized pigs whether IP impacts on Cx43 phosphorylation by measuring the density of nonphosphorylated and total Cx43 (confocal laser) during normoperfusion and 90-min ischemia in non-preconditioned and preconditioned hearts. Co-localization of PKCα, p38MAPKα, and p38MAPKβ with Cx43 and the activity of p38MAPK were assessed. IP by 10 min ischemia and 15 min reperfusion reduced IS. Non-phosphorylated Cx43 remained unchanged during ischemia in preconditioned hearts, while it increased from 35±3 to 75±8 AU (P<0.05) in nonpreconditioned hearts. Co-localization of PKCα, p38MAPKα, and p38MAPKβ with Cx43 during ischemia increased only in preconditioned hearts. While the ischemia-induced increase in p38MAPKα activity was comparable in preconditioned and non-preconditioned hearts, p38MAPKβ activity was increased only in preconditioned hearts. Blockade of p38MAPK by SB203580 attenuated the IS-reduction and the increased p38MAPK-Cx43 co-localization by IP. We conclude that IP increases co-localization of protein kinases with Cx43 and preserves phosphorylation of Cx43 during ischemia.
The conductance and permeability of gap junctions and hemichannels are regulated by modification of the cytoplasmic domains of Cx43, which are species-and tissue-specific (3) . Changes in the intracellular proton (4-6) and calcium concentrations (5, 7) and/or phosphorylation of specific serine, threonine, and tyrosine residues (for review, see Ref. 8) gradually regulate the conductance and permeability of gap junctions and hemichannels (9) . The conductance and permeability of connexons and hemichannels are increased once Cx43 becomes dephosphorylated (10) (11) (12) , whereas increased phosphorylation of Cx43 reduces their conductance and permeability (13) . Cx43 is phosphorylated by protein kinase C (PKC, α and ε) (14) (15) (16) and protein tyrosine kinases (PTK, such as src) (17) (18) (19) . More recently, mitogen activated protein kinases (MAPK), such as p42 and p44 erk (20) (21) (22) (23) , BMK-1 (24), p38 (20) , and jnk (25, 26) have been implicated in the regulation of Cx43 expression and phosphorylation.
In normal myocardium, most of Cx43 is phosphorylated (1). However, once myocardial blood flow is compromised, not only the total content of Cx43 is decreased over time (27) but also the content of non-phosphorylated Cx43 increases, as recently demonstrated in isolated bufferperfused rat hearts (28) . Dephosphorylation of Cx43 with subsequently increased conductance and permeability of gap junctions and hemichannels has been suggested to be causally involved in the propagation of ischemia/reperfusion injury, and indeed uncoupling of Cx43 using heptanol infusion during reperfusion reduced cell death in isolated rat hearts (LDH-release) and attenuated infarct size (TTC-staining) in pig hearts in vivo (29) . However, the latter finding is contrasted by two recent reports in which pretreatment with heptanol did not reduce infarct size following ischemia/reperfusion in isolated mice (30) and rabbit hearts (31) .
The signal transduction cascade involved in infarct size reduction by ischemic preconditioning includes activation of several protein kinases, such as PKC, PTK, and MAPK (for review, see Ref. 32) , which all can phosphorylate Cx43 (8) . Blockade of p38MAPK, before or following the preconditioning ischemia by SB203580, attenuates the infarct size reduction by ischemic preconditioning in pigs (33) .
Cx43 has recently been suggested to act as one end-effector of preconditioning's protection (34) and, indeed, in isolated mice hearts uncoupling of Cx43 by pretreatment with heptanol abolished infarct size reduction by ischemic preconditioning (30) . Similar results were obtained in heterozygous Cx43-deficient mice in vivo, in which ischemic preconditioning did not reduce infarct size (35) .
Whether or not ischemic preconditioning modifies the phosphorylation of Cx43 during ischemia, however, is unclear at present. We therefore studied-for the first time-non-phosphorylated and total Cx43 during normoperfusion, ischemia and reperfusion in non-preconditioned and preconditioned hearts in vivo. We also assessed the co-localization of PKCα, PKCε, p38MAPKα, and p38MAPKβ with Cx43 at the level of cell-cell contacts, and we measured the activity of p38MAPK. In a subset of experiments, infarct size and p38MAPK co-localization with Cx43 was studied in hearts in which an intracoronary infusion of the p38MAPK inhibitor SB203580 was started before the preconditioning ischemia and maintained until the end of the sustained ischemia.
Studies were performed in a well established in vivo pig model of ischemic preconditioning, in which sequential biopsies for histological and Western blot analyses can be obtained together with measurements of infarct size and regional myocardial blood flow (36) .
MATERIALS AND METHODS
The experimental protocols used in the present study were approved by the Bioethical Committee of the district of Düsseldorf, and they adhere to the guiding principles of the American Physiological Society.
Experimental preparation
Twenty-two Göttinger minipigs (20-40 kg) of either sex were initially sedated by using ketamine hydrochloride (1 g intramuscularly) and were then anesthetized with thiopental (Trapanal, 500 mg, intravenously). Through a midline cervical incision, the trachea was intubated for connection to a respirator (Dräger, Lübeck, Germany). Anesth110esia was then maintained by using enflurane (1-1.5%) with an oxygen/nitrous oxide mixture (40%:60%). Arterial blood gases were monitored frequently in the initial stages of the preparation until stable and then periodically throughout the study (Radiometer, Copenhagen, Denmark). Rectal temperature was monitored and maintained between 37-38°C by the use of a heated surgical table and drapes. The common carotid arteries were cannulated with polyethylene catheters, one to measure arterial pressure and the other to supply blood to the extracorporeal circuit. The jugular veins were cannulated for volume replacement by using warmed 0.9% NaCl and for the return of blood to the animal from the coronary venous line.
A left lateral thoracotomy was performed in the fourth intercostal space, and the pericardium was opened. A micromanometer (P7, Konigsberg Instr., Pasadena, CA) was placed in the left ventricle through the apex together with a saline-filled polyethylene catheter (used to calibrate the micromanometer in situ). The left anterior descending (LAD) coronary artery was dissected over a distance of 1.5 cm, ligated, cannulated, and perfused from an extracorporeal circuit. Prior to coronary cannulation, the pigs were anticoagulated with 20,000 IU sodium heparin; additional doses of 10,000 IU were administered hourly. The system included a roller pump, windkessel, and a side-port for the injection of radiolabeled microspheres. Coronary arterial pressure was measured from the sidearm of a polyethylene T-connector (Cole-Parmer, Chicago, IL) used as catheter tip with an external transducer (pvb Medizintechnik, Kirchseeon, Germany). Minimal coronary arterial pressure was held above 70 mmHg by adjusting the roller pump of the extracorporeal circuit to avoid hypoperfusion before ischemia. Heart rate was controlled throughout the study by left atrial pacing (Hugo Sachs Elektronik Type 215/T, Hugstetten, Germany).
Regional myocardial blood flow
Radiolabeled microspheres (15 µm in diameter; 141 Ce, 114 In, 51 Cr, 103 Ru, 95 Nb, or 46 Sc; NENDuPont, Boston, MA) were injected into the coronary perfusion circuit to determine the regional myocardial blood flow and its distribution throughout the LAD perfusion bed (model 5912, Gammaszint BF 5300 Packard, Germany).
Experimental protocols

Group 1 (90 min ischemia, n=8)
After baseline measurements of systemic hemodynamics and regional myocardial blood flow, coronary blood flow was decreased by reducing the pump speed of the extracorporeal circuit to reduce coronary arterial pressure to ~30 mmHg. This level of hypoperfusion was maintained for 90 min. Measurements of systemic hemodynamics and blood flow were repeated at 5 and 85 min ischemia. Following 90 min ischemia, the myocardium was reperfused for 120 min to facilitate the identification of necrotic tissue. At baseline, 5 and 85-90 min ischemia-and in a subset of three experiments also at 30 min reperfusion-myocardial biopsies were taken for morphological and Western blot analyses from the anterior free wall distal to the first diagonal branch of the cannulated left anterior descending coronary artery. Visual inspection during myocardial ischemia revealed that the biopsies were clearly within the perfusion territory (indicated by the cyanotic blue color). The morphological analyses were performed in viable tissue sections to avoid artifacts by irreversible tissue injury.
Group 2 (ischemic preconditioning+90 min ischemia, n=9)
After baseline measurements, the myocardium was subjected to 10 min of preconditioning ischemia with a reduction in coronary inflow to obtain a coronary arterial pressure of ~30 mmHg and then reperfused for 15 min. After reperfusion, coronary blood flow was once again reduced to the same level as during the preconditioning ischemia. Thereafter, the protocol was identical to that of Group 1.
Group 3 (SB203580+ischemic preconditioning+90 min ischemia, n=5)
After baseline measurements, the infusion of SB203580 into the cannulated left anterior descending coronary artery was started at a rate to obtain a blood concentration of ~10 µM; the infusion was maintained until the end of the 90 min ischemic period. Thirty minutes after the start of the SB203580 infusion, the myocardium was subjected to 10 min of preconditioning ischemia with a reduction in coronary inflow to obtain a coronary arterial pressure of ~30 mmHg and then reperfused for 15 min. After reperfusion, coronary blood flow was once again reduced to the same level as during the preconditioning ischemia. Thereafter, the protocol was identical to that of Group 1.
Total and non-phosphorylated Cx43
Paraffin-embedded specimens taken from the anterior myocardium at baseline, 5 and 85 min ischemia were cut into 4 µm sections, de-waxed, and rehydrated with graded alcohols and rinsed in phosphate-buffered saline (PBS). Sections were pretreated with 0.01 M citrate buffer for anitgen retrieval and then incubated with primary rabbit polyclonal anti-human Cx43 antibodies (Cat. No. 71-0700, Zytomed, Berlin, Germany) and mouse monoclonal anti-human nonphosphorylated Cx43 (Cat. No. 13-8300, Zytomed) for 1 h at 37°C in antibody diluent (1:100, Dako S3022, Copenhagen, Denmark). The antibody against the non-phosphorylated Cx43 recognizes the epitope Ser 368 (Zytomed) at the cytoplasmic domain, which is a phosphorylation site of PKC α, β, or γ (8, 14) . Two fluochrome-labeled secondary antibodies were applied: TRITC conjugated donkey anti-rabbit (sc 2095, Santa Cruz Biotechnology, CA) and FITC conjugated goat anti-mouse (sc 2078). Negative controls included omission of primary antibodies. The samples were coverslipped in Vectashield (H-1000, Vector Laboratories, Burlingame, CA) and examined by laser scan microscopy (Pascal, Zeiss, Jena, Germany) at 630× magnification.
Co-localization of PKCα, PKCε, p38MAPKα, and p38MAPβ with Cx43
Sections were pretreated as described above and then incubated with primary rabbit polyclonal anti-human Cx43 antibodies (Cat. No. 71-0700, Zytomed) and either goat polyclonal anti-human PKCα (sc208-G) or goat polyclonal anti-human PKCε (sc214-G) for 1 h at 37°C in antibody diluent (1:100, Dako S3022). In additional analyses, no signal for PKCδ (sc937-G goat polyclonal anti-human) and only a weak signal for PKCβ (sc209-G polyclonal anti-human) were detected; therefore, only PKCα and ε were analyzed and these PKC isoforms have previously been described to be the major isoforms in hearts of mammals (15, 32, 37) , including humans (16).
Furthermore, sections were incubated with mouse monoclonal anti-human p38MAPKα (Cat. No. 33-1300, Zytomed) or mouse monoclonal anti-human p38MAPKβ2 (Cat. No. 338700, Zytomed) for 1 h at 37°C in antibody diluent (1:100, Dako S3022). Fluochrome-labeled secondary antibodies were applied: TRITC conjugated donkey anti-rabbit (sc2095), FITC conjugated donkey anti-goat IgG (sc2024), and FITC conjugated goat anti-mouse (sc2078). Negative controls included omission of primary antibodies. The samples were coverslipped in Vectashield (H-1000, Vector Laboratories) and examined by confocal laser scan microscopy at 630× magnification.
Immunohistochemistry
Tissue sections were analyzed in a blinded fashion by a person who did not know the assignment of a given tissue section to the experimental protocol (group and time point). From each tissue section, five fields of view at an optimal focus were photographed and the intercalated disks were defined as areas of cell-cell contact displaying a detectable density of total Cx43 (red staining) (Fig. 1) . The density units of Cx43 (total and non-phosphorylated) or the respective protein kinases were obtained for the defined intercalated disk regions. The changes observed during ischemia were expressed as percent of the respective baseline values.
PKCα and PKCε protein contents
Cytosolic and membrane fractions were obtained, as described previously (38) . Briefly, tissues were homogenized in 10 volumes of buffer A (20 mM Tris, 2 mM EGTA, 1 mM DTT, 1 mM PMSF, 50 µg/ml soybean trypsin inhibitor, 10 µM pepstatin A, 10 µM leupeptin, and 2 µg/ml aprotinin at pH 7.4). The homogenates were centrifuged twice for 20 min at 50,000 g, and the combined supernatants were considered as the cytosolic extract; the washed pellet was resuspended in buffer A containing 1% Triton X-100, incubated for 30 min at 4°C, and centrifuged twice again for 20 min at 50,000 g; the combined supernatants were used as the membrane extract. Samples were boiled in sodium dodecyl sulfate-buffer at 95°C and applied to 9% polyacrylamide gels. The proteins were separated by electrophoresis (25 µA, for 2 h at 4°C) and transferred to nitrocellulose membranes by electroblotting (40 V, overnight, at 4°C). After overnight incubation at 4°C with the primary antibodies for PKCα or PKCε and extensive washing, blots were transferred to blocking buffer containing secondary antibodies linked to horseradish peroxidase (phototope horseradish peroxidase detection kit, New England Biolabs, Frankfurt, Germany) and incubated for 1 h at room temperature. Finally, blots were incubated in LumiGlo substrate protein (Amersham Pharmacia Biotech, London, UK) for 1 min, wrapped in plastic, and opposed to imaging film for 1 to 2 min to detect the chemiluminescent signal. Films were processed by routine methods and analyzed by quantitative two-dimensional densitometry by using commercially available software (Herolab, Wiesloch, Germany).
p38MAPK-activity
The tissue samples were weighed, diluted with cell lysis buffer (1:10, added 1 mM PMSF Cell Signaling Technology Inc., Beverly, MA), sonicated 4 times for 5 s on ice and centrifuged at 14,000 g for 10 min at 4°C. A mouse monoclonal anti-human p38MAPKα or anti-human p38MAPKβ antibody was used to selectively immunoprecipitate the respective isoform of p38MAPK from each supernatant. The resulting immunoprecipitates were incubated with ATF-2 fusion protein in the presence of ATP and kinase buffer for 30 min at 30°C to phosphorylate ATF-2. Phosphorylation of ATF-2 at Thr71 was measured by Western blotting using a phospho-ATF-2 (Thr71) antibody (Cell Signaling Technology, Frankfurt, Germany). Activity of p38MAPKα or p38MAPKβ, as derived from the phosphorylation of ATF-2, was normalized to the total protein content of the respective biopsy, and activity during ischemia was expressed as percent of the respective baseline values.
The total protein content was determined by the BCA Protein Assay Kit (Pierce, Rockford, IL), which is based on bicinchoninic acid for the colorimetric detection and quantification of the total protein content. A standard curve was generated by plotting the average blank-corrected absorbances (562 µm) against the concentrations (µg/ml) of bovine serum albumin standards. Using this standard curve, total protein concentrations of individual biopsies were calculated.
The specificity of the above antibodies was tested in neonatal rat ventricular cardiomyocytes transfected with either p38MAPKα or p38MAPKβ (39) . Using the same analytical procedure as described above, ATF2-phosphorylation following immunoprecipitation with the mouse monoclonal anti-human p38MAPKα antibody was detected only in p38MAPKα transfected cardiomyocytes, while no signal was derived from p38MAPKβ transfected cardiomyocytes. Similarly, ATF2-phosphorylation following immunoprecipitation with the mouse monoclonal anti-human p38MAPKβ antibody was detected only in p38MAPKβ transfected cardiomyocytes.
Statistics
Data are reported as mean values ± SEM. Systemic hemodynamics, as well as immunohistochemistry and Western blot data, were compared by two-way ANOVA followed by Fisher's least-square difference test using SYSTAT software (SPSS Science, Chicago, IL). Subendocardial blood flow at 5 min ischemia, area at risk, and infarct size were compared by one-way ANOVA. A P-value less than 0.05 was accepted as indicating a significant difference.
RESULTS
Heart rate, left ventricular pressure, LVdP/dt, coronary arterial pressure, and coronary blood flow were similar between non-preconditioned and preconditioned hearts without or with SB203580 throughout the protocol (Table 1) . Ischemic regional myocardial blood flow was 0.052±0.009, 0.040±0.008, and 0.052±0.012 ml/min/g in non-preconditioned and preconditioned hearts in the absence or presence of SB203580, respectively. Infarct size was reduced from 25.5±4.2 to 10.3±2.3% of the area at risk (P<0.05) by ischemic preconditioning, but remained at 20.0±3.9% in preconditioned hearts receiving SB203580.
Cx43
The density of total Cx43 and non-phosphorylated Cx43 at the intercalated disks did not differ between non-preconditioned and preconditioned hearts at baseline (see representative example in Fig. 2 ). At 5 min of the sustained ischemia, all measured parameters remained unchanged in nonpreconditioned and preconditioned hearts (Fig. 2, 3) . However, prolongation of ischemia to 85-90 min induced marked changes in the density of total and non-phosphorylated Cx43 in the nonpreconditioned hearts; i.e., total Cx43 decreased while non-phosphorylated Cx43 increased (Figs.  2, 3 ). In contrast, in preconditioned hearts both total Cx43 and non-phosphorylated Cx43 remained stable (Figs. 2, 3 ).
At 30 min reperfusion, the density of non-phosphorylated Cx43 returned toward baseline values in non-preconditioned hearts (Figs. 2, 3) . In preconditioned hearts receiving SB203580, the density of both total and non-phosphorylated Cx43 remained unaltered throughout the experimental protocol.
Co-localization of PKCα and PKCε with Cx43
The density of PKCα (91±7 vs. 90±6 AU) and PKCε (106±6 vs. 113±5 AU), at the intercalated disks did not differ between non-preconditioned and preconditioned hearts at baseline. At 5 min of the sustained ischemia, no significant change in the co-localization of Cx43 with either protein kinase was observed in non-preconditioned and preconditioned hearts. With prolongation of ischemia to 85-90 min, the co-localization of PKCα (85±9 AU) with Cx43 at the intercalated disks remained unchanged in non-preconditioned hearts. Also at 30 min reperfusion, the colocalization of PKCα (87±10 AU) with Cx43 at the intercalated disks remained unchanged in non-preconditioned hearts. In contrast, the co-localization of PKCα with Cx43 was increased in preconditioned hearts at 85-90 min ischemia (103±3 AU) (P<0.05 vs. baseline and nonpreconditioned hearts) and at 30 min reperfusion (105±7 AU).
PKCε co-localization with Cx43 remained completely unaltered in non-preconditioned (106±6 vs. 104±7 vs. 107±10 AU, baseline vs. 85-90 min ischemia vs. 30 min reperfusion) and preconditioned (112±5 vs. 105±6 vs. 104±9 AU, baseline vs. 85-90 min ischemia vs. 30 min reperfusion) hearts.
PKCα and PKCε protein contents
At 5 and 85 min ischemia, the expression of PKCα in the cytosolic fraction tended to be increased in non-preconditioned (124±15% and 121±20% of baseline, respectively) and preconditioned (139±28% and 145±32% of baseline, respectively) hearts. Expression of PKCα in the membrane fraction was increased at 5 min ischemia in non-preconditioned (203±33% of baseline, P<0.05) and preconditioned (281±117% of baseline, P<0.05) hearts, without any significant difference between groups. The increased expression of PKCα at the membrane was preserved even when ischemia was prolonged to 85-90 min (232±40% and 269±113% of baseline, respectively, P<0.05). No significant change in PKCε within the cytosolic or the membrane fraction was detected in either group throughout ischemia.
Co-localization of p38MAPKα and p38MAPKβ with Cx43
The density of p38MAPKα (94±2 vs. 89±2 AU) and p38MAPKβ (74±4 vs. 75±4 AU) at the intercalated disks did not differ between non-preconditioned and preconditioned hearts at baseline. At 5 min of the sustained ischemia, no significant change in the co-localization of Cx43 with either kinase was observed in non-preconditioned and preconditioned hearts. With prolongation of ischemia to 85-90 min, the co-localization of p38MAPKα (95±1 AU) and p38MAPKβ (76±5 AU) with Cx43 at the intercalated disks remained unchanged in nonpreconditioned hearts. In contrast, the co-localization p38MAPKα (101±2 AU) and p38MAPKβ (89±4 AU) with Cx43 was increased in preconditioned hearts (all P<0.05 vs. baseline and nonpreconditioned hearts). At 30 min reperfusion, the co-localization of p38MAPKα (95±4 AU) and p38MAPKβ (85±3 AU) with Cx43 at the intercalated disks were not significantly different from baseline in non-preconditioned hearts, but both the co-localization of p38MAPKα (114±6 AU) and p38MAPKβ (101±5 AU) with Cx43 remained elevated in preconditioned hearts.
Intracoronary infusion of SB203580 attenuated the co-localization of p38 MAPKα and p38MAPKβ with Cx43 at 85 min ischemia (Fig. 4, Insert) . Neither the infarct size reduction nor the increased co-localization achieved by ischemic preconditioning were completely blocked following SB203580. Moreover, a significant correlation between the increased co-localization of p38 MAPKβ with connexin 43 at 85 min ischemia and the reduction in infarct size was observed in the preconditioned hearts in the absence (Fig. 4, circle) or presence of SB203580 (Fig. 4, squares) . Such close correlation was not detected for the increased co-localization of p38MAPKα with connexin 43 at 85 min ischemia and the reduction in infarct size (y=0.49x-41.96, r=0.44).
p38MAPKα or p38MAPKβ activity
A representative blot of p38MAPKβ activity is given in Fig. 5 . The activity of p38MAPKα was increased at 5 min and more so at 85 min ischemia in non-preconditioned hearts and preconditioned hearts (Fig. 6) . In contrast, while p38MAPKβ activity was increased in nonpreconditioned and preconditioned hearts at 5 min ischemia, at 85-90 min ischemia it remained increased only in preconditioned hearts (Fig. 5 and 6 ).
DISCUSSION
The present study demonstrates for the first time in vivo that dephosphorylation of Cx43 occurs during sustained ischemia. Such dephosphorylation of Cx43 is completely abolished by ischemic preconditioning. Furthermore, the co-localization of certain protein kinases with Cx43 at the intercalated disks is increased by ischemic preconditioning. Finally, the present study demonstrates for the first time a differential activation pattern of p38MAPKα and p38MAPKβ activity during sustained ischemia in non-preconditioned vs. preconditioned hearts.
Cx43
In isolated buffer-perfused rat hearts, Cx43 is dephosphorylated during sustained ischemia (28) . This result was confirmed in the present study in in vivo pig hearts. Dephosphorylation of Cx43 increases the permeability of gap junctions and hemichannels (for review, see Ref. 8) , thus contributing to the propagation of ischemia/reperfusion injury (29) . In support of this idea, ischemic preconditioning reduced infarct size and completely abolished the dephosphorylation of Cx43 in the present study.
Functional gap junctions and/or hemichannels are necessary for the signal transduction of ischemic preconditioning, since uncoupling of gap junctions and/or hemichannels by pretreatment with heptanol (30) or the reduction in the number of functional gap junctions and/or hemichannels in heterozygous deficiency of Cx43 (35) abolished ischemic preconditioning's protection in mice hearts.
Such an ambivalent role-that is, involvement not only in ischemia/reperfusion damage but also in ischemic preconditioning's protection-has also been demonstrated for free radicals: free radicals per se contribute to irreversible tissue injury during sustained ischemia (40) , but free radicals are also involved in the signal transduction cascade of ischemic preconditioning's protection (41) (42) (43) (44) .
PKCα and PKCε
PKCε is an established mediator of ischemic preconditioning in mice and rabbits (32), and PKCε is involved in signaling complexes with at least 36 proteins in mice (45) (46) (47) , among them Cx43 (37) . Indeed, activated PKCε co-localizes with Cx43 and contributes to phosphorylation of Cx43 in rats (15) .
In larger mammals PKCα appears to be more important for ischemic preconditioning's protection (32), and indeed, although in the present study both PKCα and PKCε were expressed in the membrane fraction at baseline, only PKCα expression was significantly increased by ischemia/reperfusion. PKCα contributes to phosphorylation of Cx43 at its cytoplasmic domain Ser 368 in rats in vitro (8, 14) . Since the antibody directed against the non-phosphorylated Cx43 recognizes Ser 368 , it appears likely that the increased co-localization of PKCα with Cx43 at the intercalated disks in preconditioned hearts contributes to the preservation of Cx43 phosphorylation. In humans, both activated PKCα and PKCε co-localize with Cx43 (16) . Whether PKCε is also required for Cx43 phosphorylation in pigs remains unknown at present. p38MAPK p38MAPK is phosphorylated within minutes during global or regional no-flow ischemia in isolated rat hearts as well as in rat, dog, and pig hearts in vivo (for review, see Refs. 32 and 48). With prolongation of ischemia, however, the phosphorylation of p38MAPK may be reduced toward pre-ischemic values, whereas phosphorylation is once again increased upon reperfusion (49, 50) . Both p38MAPKα and p38MAPKβ isoforms are expressed within the heart and appear to mediate opposing biological functions (for review, see Ref. 48 ). The present study for the first time demonstrates that both p38MAPKα and p38MAPKβ activities are increased at 5 min ischemia in non-preconditioned and preconditioned hearts; however, while the activity of p38MAPKα remains elevated with prolongation of ischemia in both non-preconditioned and preconditioned hearts, p38MAPKβ activity remains increased in preconditioned hearts but is once again decreased toward baseline values in non-preconditioned hearts. Apart from differences in p38MAPK activity, p38MAPKα and p38MAPKβ isoforms co-localize with Cx43 and such co-localization is increased during sustained ischemia only in preconditioned hearts. Such increased co-localization of p38MAPKα and p38MAPKβ with Cx43 is prevented by SB203580 as is the infarct size reduction by ischemic preconditioning.
Similarly, increased Cx43 phosphorylation following angiotensin II stimulation is mediated by p38MAPK in neonatal rat ventricular cardiomyocytes (20) , since it was abolished by the p38MAPK antagonist SB202190.
In the present study, we did not present p38 MAPK α and β activity data in vivo following treatment with SB203580. Because SB203580 is a reversible inhibitor of p38 MAPK activity (51, 52) , the immunoprecipitation procedure washes SB203580 off to a significant extent (53, 54) , resulting in a renewed catalytic activity of p38 MAPK. To avoid such renewed catalytic activity of p38 MAPK, arbitrary concentrations of SB203580 must be added to the p38 MAPK activity assay (53) . Whether such arbitrary inhibitor concentrations truly reflect the in vivo concentrations, however, is unknown. We therefore refrained from presenting the p38 MAPK activity in SB203580-treated hearts.
Apart from an increased activity and co-localization of certain protein kinases, a decreased activity of protein phosphatases could also explain the maintained phosphorylation of Cx43 in preconditioned hearts. While protein phosphatase 1 appears to be involved in hypoxic preconditioning in isolated rat cardiomyocytes (55) , and blockade of protein phosphatases with fostriecin can mimic ischemic preconditioning's protection (56) , the activity of the protein phosphatases 1 and 2A remains unaltered in ischemic preconditioned compared with nonpreconditioned hearts (56), thus making a causal role of phosphatases in the maintained Cx43 phosphorylation unlikely.
Phosphorylation of Cx43 will decrease the permeability and conductance of gap junctions and hemichannels. Whether the modulation of the permeability and conductance of either gap junctions and thus cell-cell communication or hemichannels and thus volume regulation or both are responsible for the cardioprotection obtained by ischemic preconditioning remains unknown at present and requires further in vitro studies.
In conclusion, ischemic preconditioning increases the co-localization of protein kinases with Cx43 and preserves the phosphorylation of Cx43 during sustained ischemia in in vivo pig hearts. preconditioned heart (left side) and a preconditioned heart (right side). While in non-preconditioned hearts the density of non-phosphorylated Cx43 at the intercalated disks increased during 85 min ischemia (yellow color), the density remained unchanged in preconditioned hearts. At 30 min reperfusion, however, the density of non-phosphorylated Cx43 at the intercalated disks returned toward baseline values. ischemia, total Cx43 and non-phosphorylated Cx43 remained unchanged in non-preconditioned and preconditioned hearts. However, prolongation of ischemia to 85 min reduced the density of total Cx43 and increased the density of nonphosphorylated Cx43 in non-preconditioned hearts. In contrast, in preconditioned hearts both the density of total and nonphosphorylated Cx43 remained unchanged. At 30 min reperfusion, however, the density of non-phosphorylated Cx43 at the intercalated disks returned toward baseline values.*P < 0.05 vs. Baseline; #P < 0.05 vs. preconditioned hearts. Cx43 at 85 min ischemia. Neither the infarct size reduction nor the increased co-localization achieved by ischemic preconditioning were completely blocked with SB203580. A significant correlation between the increased co-localization of p38 MAPKβ with connexin 43 at 85 min ischemia and the reduction in infarct size was observed in preconditioned hearts in the absence (Figure 4 , circle) or presence of SB203580 (Figure 4 , squares). *P < 0.05 vs. placebo #P < 0.05 vs. ischemic preconditioning. . Representative examples of p38MAPKβ activity from a non-preconditioned heart and a preconditioned heart. While p38MAPKβ activity was increased in non-preconditioned and preconditioned hearts at 5 min ischemia, at 85-90 min ischemia it remained increased only in preconditioned hearts.
Fig. 6
Figure 6. The activity of p38MAPKα was increased to a comparable extent at 5 min and 85 min ischemia over baseline in non-preconditioned and preconditioned hearts. In contrast, while p38MAPKβ activity tended to be increased in non-preconditioned and preconditioned hearts at 5 min ischemia, at 85 min ischemia it remained increased only in preconditioned hearts. *P < 0.05 vs. baseline; #P < 0.05 vs. non-preconditioned hearts.
